Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
Bulios Fair Price
$10.42
17.0% downside
Trenutna cena
$12.56
Po podatkih Bulios Fair Price je delnica CRVS trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
O podjetju
Corvus Pharmaceuticals, Inc. (CRVS) is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of various types of cancer. Their primary goal is to discover and develop innovative therapies targeting the immune system that focus on specific immune pathways and interactions between tumors and the host immune system. Among their main products are drugs based on immune checkpoint inhibitors and immune response modulators, which have the potential to improve the treatment of various types of cancer and increase patient survival.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Richard A. Miller
Employees
37
Headquarters
South San Francisco
Prihajajoči dogodki
Earnings
Upcoming earnings report